Literature DB >> 33741007

Hip pathologies in mucopolysaccharidosis type III.

Sandra Rafaela Breyer1,2,3, Eik Vettorazzi4, Leonie Schmitz4, Amit Gulati4, Katharina Maria von Cossel5,6, Alexander Spiro7,8,5, Martin Rupprecht7,8,5, Ralf Stuecker7,8,5, Nicole Maria Muschol5,6.   

Abstract

BACKGROUND: Mucopolysaccharidosis type III (MPS III) comprises a group of rare lysosomal storage diseases. Although musculoskeletal symptoms are less pronounced than in other MPS subtypes, pathologies of hip and spine have been reported in MPS III patients. The purpose of this study was to describe hip pathologies and influencing parameters in MPS III patients.
METHODS: A retrospective chart review was performed for 101 MPS III patients. Thirty-two patients met the inclusion criteria of enzymatically or genetically confirmed diagnosis and anteroposterior radiograph of the hips. Modified Ficat classification, Wiberg's center-edge angle, and Reimer's migration percentage were measured.
RESULTS: The mean age at data assessment was 11.0 years (SD 5.7). Osteonecrosis of the femoral head was observed in 17/32 patients. No statistically significant association was found between these changes and age, sex, or MPS III subtype. Patients with a severe phenotype showed significantly higher rates of osteonecrosis (14/17) than patients with an intermediate phenotype. Hip dysplasia was present in 9/32 patients and was significantly associated with osteonecrosis of the femoral head (p = 0.04).
CONCLUSIONS: The present study demonstrates a high rate of hip pathologies in MPS III patients. Hip dysplasia and severe phenotype were significantly correlated with osteonecrosis of the femoral head. Therefore, radiographs of the hips are highly recommended in baseline and follow-up assessments of MPS III patients. TRIAL REGISTRATION: Retrospectively registered.

Entities:  

Keywords:  Dysostosis multiplex; Femoral head; Hip dysplasia; MPS; Mucopolysaccharidosis type III; Osteonecrosis; Pain; Sanfilippo syndrome; Skeletal disease; Skeletal dysplasia

Year:  2021        PMID: 33741007     DOI: 10.1186/s13018-021-02340-6

Source DB:  PubMed          Journal:  J Orthop Surg Res        ISSN: 1749-799X            Impact factor:   2.359


  21 in total

Review 1.  Molecular genetics of mucopolysaccharidosis type IIIA and IIIB: Diagnostic, clinical, and biological implications.

Authors:  G Yogalingam; J J Hopwood
Journal:  Hum Mutat       Date:  2001-10       Impact factor: 4.878

2.  Cumulative incidence rates of the mucopolysaccharidoses in Germany.

Authors:  F Baehner; C Schmiedeskamp; F Krummenauer; E Miebach; M Bajbouj; C Whybra; A Kohlschütter; C Kampmann; M Beck
Journal:  J Inherit Metab Dis       Date:  2005       Impact factor: 4.982

3.  Orthopedic management of mucopolysaccharide disease.

Authors:  Klane K White; Paul Harmatz
Journal:  J Pediatr Rehabil Med       Date:  2010

Review 4.  Management of mucopolysaccharidosis type III.

Authors:  M A Cleary; J E Wraith
Journal:  Arch Dis Child       Date:  1993-09       Impact factor: 3.791

Review 5.  Musculoskeletal manifestations of Sanfilippo Syndrome (mucopolysaccharidosis type III).

Authors:  Klane K White; Lori A Karol; Dustin R White; Susan Hale
Journal:  J Pediatr Orthop       Date:  2011 Jul-Aug       Impact factor: 2.324

6.  High prevalence of femoral head necrosis in Mucopolysaccharidosis type III (Sanfilippo disease): a national, observational, cross-sectional study.

Authors:  Jessica de Ruijter; Mario Maas; Anneloes Janssen; Frits A Wijburg
Journal:  Mol Genet Metab       Date:  2013-03-16       Impact factor: 4.797

Review 7.  Bone, joint and tooth development in mucopolysaccharidoses: relevance to therapeutic options.

Authors:  E Oussoren; M M M G Brands; G J G Ruijter; A T van der Ploeg; A J J Reuser
Journal:  Biochim Biophys Acta       Date:  2011-07-30

8.  Expression and characterization of wild type and mutant recombinant human sulfamidase. Implications for Sanfilippo (Mucopolysaccharidosis IIIA) syndrome.

Authors:  K J Perkins; S Byers; G Yogalingam; B Weber; J J Hopwood
Journal:  J Biol Chem       Date:  1999-12-24       Impact factor: 5.157

9.  Mechanism of glycosaminoglycan-mediated bone and joint disease: implications for the mucopolysaccharidoses and other connective tissue diseases.

Authors:  Calogera M Simonaro; Marina D'Angelo; Xingxuan He; Efrat Eliyahu; Nataly Shtraizent; Mark E Haskins; Edward H Schuchman
Journal:  Am J Pathol       Date:  2007-12-13       Impact factor: 4.307

10.  Scoring evaluation of the natural course of mucopolysaccharidosis type IIIA (Sanfilippo syndrome type A).

Authors:  Ann Meyer; Kai Kossow; Andreas Gal; Chris Mühlhausen; Kurt Ullrich; Thomas Braulke; Nicole Muschol
Journal:  Pediatrics       Date:  2007-10-15       Impact factor: 7.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.